Of all of the candidate biomarkers identified in our signature, Sox-2 and caveolin-1 demonstrated the largest overall change between the cetuximab-resistant and -sensitive HNSCC PDX clusters. Here, SOX2 is linked to head and neck squamous cell carcinoma.